{"filing":{"accession_number":"0001104659-26-082459","cik":"0002070534","ticker":"SLBT","company_name":"SL Science Holding Ltd","form":"6-K","filing_date":"2026-07-10","report_date":null,"primary_document":"tm2620209d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2070534/000110465926082459/tm2620209d1_6k.htm"},"events":[{"id":17133,"run_id":15336,"accession_number":"0001104659-26-082459","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"SL Science announced submission of an Orphan Drug Designation (ODD) request to the FDA for its Vdelta2+ Gamma Delta T cell therapy targeting glioblastoma. This is a material regulatory milestone in the company's clinical development strategy for a key product candidate. While not a discrete M\u0026A, financing, or governance event, the ODD submission represents a significant operational and strategic advancement in bringing an innovative cancer therapy toward clinical development, with potential access to accelerated FDA review pathways—a material event for a biotech company's pipeline progress.","company_name":"SL Science Holding Ltd","ticker":"SLBT","filing_date":"2026-07-10","form":"6-K","submitted_at":null,"items":[{"id":15469,"accession_number":"0001104659-26-082459","item_number":"EX-99.1","item_title":"tm2620209d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"SL Science announced submission of an Orphan Drug Designation (ODD) request to the FDA for its Vdelta2+ Gamma Delta T cell therapy targeting glioblastoma. This is a material regulatory milestone in the company's clinical development strategy for a key product candidate. While not a discrete M\u0026A, financing, or governance event, the ODD submission represents a significant operational and strategic advancement in bringing an innovative cancer therapy toward clinical development, with potential access to accelerated FDA review pathways—a material event for a biotech company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:56:38.259121+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15469,"accession_number":"0001104659-26-082459","item_number":"EX-99.1","item_title":"tm2620209d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"SL Science announced submission of an Orphan Drug Designation (ODD) request to the FDA for its Vdelta2+ Gamma Delta T cell therapy targeting glioblastoma. This is a material regulatory milestone in the company's clinical development strategy for a key product candidate. While not a discrete M\u0026A, financing, or governance event, the ODD submission represents a significant operational and strategic advancement in bringing an innovative cancer therapy toward clinical development, with potential access to accelerated FDA review pathways—a material event for a biotech company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:56:38.259121+00:00","company_name":"SL Science Holding Ltd","ticker":"SLBT","filing_date":"2026-07-10"}]}